A carregar...
Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
Brodalumab is a fully human monoclonal antibody targeting the IL‐17 receptor A leading to an inhibition of the biological effect of IL‐17A, IL‐17F, IL‐17A/F heterodimer, IL‐17C and IL‐17E isoforms. It has shown to be efficacious in the treatment of moderate to severe plaque psoriasis (210 mg adminis...
Na minha lista:
| Publicado no: | Basic Clin Pharmacol Toxicol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6850607/ https://ncbi.nlm.nih.gov/pubmed/30661290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcpt.13202 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|